American Society of Hematology

Figure 1.

$Figure 1. Five-year follow-up of patients with relapsed/refractory (R/R) Hodgkin lymphoma who failed ASCT, treated with BV. Censored patients are indicated by black dots, patients followed through study closure and in remission without the start of new therapy other than allo-SCT are indicated by red dots. Shown are overall survival (A), overall PFS (B) and PFS by best response (C). Reprinted from Chen et al13 with permission. Copyright 2016 The American Society of Hematology.$

Five-year follow-up of patients with relapsed/refractory (R/R) Hodgkin lymphoma who failed ASCT, treated with BV. Censored patients are indicated by black dots, patients followed through study closure and in remission without the start of new therapy other than allo-SCT are indicated by red dots. Shown are overall survival (A), overall PFS (B) and PFS by best response (C). Reprinted from Chen et al¹³ with permission. Copyright 2016 The American Society of Hematology.

This Feature Is Available To Subscribers Only